WO2003031654A1 - Microreseau comprenant des sondes pour genotyper des especes de mycobacteries, pour differencier des souches de bacille de koch et pour detecter des souches resistantes aux antibiotiques - Google Patents
Microreseau comprenant des sondes pour genotyper des especes de mycobacteries, pour differencier des souches de bacille de koch et pour detecter des souches resistantes aux antibiotiques Download PDFInfo
- Publication number
- WO2003031654A1 WO2003031654A1 PCT/KR2002/001885 KR0201885W WO03031654A1 WO 2003031654 A1 WO2003031654 A1 WO 2003031654A1 KR 0201885 W KR0201885 W KR 0201885W WO 03031654 A1 WO03031654 A1 WO 03031654A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tuberculosis
- strains
- probe
- probes
- microarray
- Prior art date
Links
- 239000000523 sample Substances 0.000 title claims abstract description 186
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 141
- 238000002493 microarray Methods 0.000 title claims abstract description 56
- 238000003205 genotyping method Methods 0.000 title claims abstract description 48
- 206010034133 Pathogen resistance Diseases 0.000 title claims abstract description 39
- 238000001514 detection method Methods 0.000 title abstract description 28
- 241000894007 species Species 0.000 claims abstract description 73
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 22
- 241000186359 Mycobacterium Species 0.000 claims abstract description 20
- 208000015181 infectious disease Diseases 0.000 claims abstract description 17
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 40
- 230000035772 mutation Effects 0.000 claims description 29
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 25
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 25
- 229960001225 rifampicin Drugs 0.000 claims description 25
- 229960005206 pyrazinamide Drugs 0.000 claims description 23
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 23
- 108091023242 Internal transcribed spacer Proteins 0.000 claims description 17
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 16
- 101150013110 katG gene Proteins 0.000 claims description 9
- 101150090202 rpoB gene Proteins 0.000 claims description 8
- 229960003350 isoniazid Drugs 0.000 claims description 6
- 101150022921 pncA gene Proteins 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 abstract description 30
- 230000004069 differentiation Effects 0.000 abstract description 17
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 108020004414 DNA Proteins 0.000 description 43
- 238000003752 polymerase chain reaction Methods 0.000 description 27
- 238000009396 hybridization Methods 0.000 description 25
- 108020004705 Codon Proteins 0.000 description 22
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 18
- 230000003115 biocidal effect Effects 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 description 6
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000003252 repetitive effect Effects 0.000 description 5
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000186366 Mycobacterium bovis Species 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 229960000285 ethambutol Drugs 0.000 description 4
- 230000007614 genetic variation Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 101100366466 Caenorhabditis elegans spo-11 gene Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 108091036078 conserved sequence Proteins 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940124307 fluoroquinolone Drugs 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 108010058004 pyrazinamide deamidase Proteins 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108030002440 Catalase peroxidases Proteins 0.000 description 2
- 101150005343 INHA gene Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000187490 Mycobacterium scrofulaceum Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 fluoroquinolone (FZ) Chemical compound 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 2
- 108700022487 rRNA Genes Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003588 threonines Chemical class 0.000 description 2
- 150000003668 tyrosines Chemical class 0.000 description 2
- 102100024090 Aldo-keto reductase family 1 member C3 Human genes 0.000 description 1
- 101100306508 Bacillus subtilis (strain 168) sigB gene Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101100138691 Escherichia coli (strain K12) ptsO gene Proteins 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241000983409 Microbacterium terrae Species 0.000 description 1
- 241001508003 Mycobacterium abscessus Species 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 241000187478 Mycobacterium chelonae Species 0.000 description 1
- 241000187486 Mycobacterium flavescens Species 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 241000187485 Mycobacterium gastri Species 0.000 description 1
- 241001509451 Mycobacterium genavense Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187493 Mycobacterium malmoense Species 0.000 description 1
- 241000187492 Mycobacterium marinum Species 0.000 description 1
- 241000187919 Mycobacterium microti Species 0.000 description 1
- 241000187489 Mycobacterium simiae Species 0.000 description 1
- 241000187496 Mycobacterium szulgai Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 241000187644 Mycobacterium vaccae Species 0.000 description 1
- 241000187494 Mycobacterium xenopi Species 0.000 description 1
- 101100509674 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) katG3 gene Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010065942 Prostaglandin-F synthase Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 101150017109 fliA gene Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 101150084116 rpo4 gene Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 101150017120 sod gene Proteins 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the probes or primers used in the present invention for genotyping Mycobacteria species, differentiating M. tuberculosis strains, and detecting antibiotic-resistant strains are shown in Tables 1 , 2, and 3 below, respectively.
- kat4R 5'-biotin-CTG CAG GCG GAT GCG ACC A-3' (SEQ ID NO. 164) were prepared for PCR of the codon 463 region.
- the standard M. tuberculosis H37Rv strain, INH-resistant M. tuberculosis clinical isolates, and INH-susceptible M. tuberculosis clinical isolates were amplified using the primers by PCR.
- the M. bovis strain hybridized only to the probes SPO-01 , SPO-03, SPO-04, SPO-05, SPO-06, SPO-07, SPO-08, SPO-11 , SPO-12, SPO-12, SPO-13, SPO-17, SPO-18, SPO-19, SPO-20, SPO-21, SPO-22, SPO-23, SPO-24, SPO-25, SPO-26, SPO-27, SPO-28, SPO-29, SPO-30, SPO-31 , SPO-34, SPO-35, SPO-37, and SPO-38 in spots 50, 52, 53, 54, 55, 56, 57, 60, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 83, 84, 86, and 87 of FIG. 1 , respectively.
- FIGS. 5C and 5D show the results of an INH-resistance test when M. tuberculosis H37Rv strain that is susceptible to INH and an INH-resistant mutant with the substitution of threonine (ACC) for serine (AGC) at codon 315 of the katG gene were used as the target DNA, respectively.
- hybridization occurred in the positive control probe which is a mixture of the individual probes for both strains.
- the INH-susceptible M. tuberculosis hybridized only to the wild-type probes for codons 315 and 463, i.e., kat 315-WS and kat 463-WR in spots 44 and 47 of FIG. 1 , respectively.
- the INH-resistant mutant hybridized specifically to the probes kat 315-MT and kat 463-WR in spots 45 and 47 of FIG. 1 , respectively.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR2001/62125 | 2001-10-09 | ||
KR10-2001-0062125A KR100454585B1 (ko) | 2001-10-09 | 2001-10-09 | 마이코박테리아의 균주 감별, 결핵균의 스트레인 감별과항생제 내성을 검출하기 위한 프로브를 포함하는마이크로어레이와 이를 이용한 검출 방법 및 진단 키트 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003031654A1 true WO2003031654A1 (fr) | 2003-04-17 |
Family
ID=19714977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2002/001885 WO2003031654A1 (fr) | 2001-10-09 | 2002-10-09 | Microreseau comprenant des sondes pour genotyper des especes de mycobacteries, pour differencier des souches de bacille de koch et pour detecter des souches resistantes aux antibiotiques |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100454585B1 (fr) |
WO (1) | WO2003031654A1 (fr) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2860801A1 (fr) * | 2003-10-10 | 2005-04-15 | Bertin Technologies Sa | Methode de detection rapide de micro-organismes sur puces a adn |
WO2005078131A1 (fr) * | 2004-02-11 | 2005-08-25 | Health Protection Agency | Dosage de resistance a tb |
EP1634959A3 (fr) * | 2004-09-14 | 2006-03-22 | Samsung Electronics Co.,Ltd. | Procédé de conception d'un jeu de sondes, micro-réseau l'utilisant, support lisible par ordinateur muni d'un programme pour exécuter ladite méthode |
EP1580281A3 (fr) * | 2003-09-29 | 2006-09-13 | Eppendorf Ag | Procédé pour determiner la résistance microbienne aux antibiotiques |
WO2006097232A3 (fr) * | 2005-03-18 | 2007-02-01 | Eppendorf Ag | Detection d'une sensibilite aux antibiotiques et de facteurs de virulence chez pseudomonas aeruginosa |
WO2007018563A3 (fr) * | 2004-10-05 | 2007-06-21 | Wyeth Corp | Ensembles de sondes de detection de multiples souches de differentes especes |
US7332597B2 (en) | 2004-06-28 | 2008-02-19 | University Of Kentucky Research Foundation | Primers and probe to identify mycobacterium tuberculosis complex |
CN1995380B (zh) * | 2006-01-05 | 2010-05-12 | 中国人民解放军总医院第二附属医院 | 一种检测和鉴定分枝杆菌菌种的方法及其专用试剂盒 |
EP2179041A4 (fr) * | 2007-06-22 | 2010-12-22 | Ibis Biosciences Inc | Compositions et procédés permettant d'identifier des caractéristiques de sous-espèces de mycobacterium tuberculosis |
JP2013502922A (ja) * | 2009-08-26 | 2013-01-31 | エルジー ライフ サイエンス リミテッド | M.ツベルクローシス(m.tuberculosis)群、およびマイコバクテリア(mycobacteria)属を検出するための組成物と、同組成物を用いたマルチプレックスリアルタイムpcrによりm.ツベルクローシス(m.tuberculosis)群、およびマイコバクテリア(mycobacteria)属を同時に検出する方法 |
EP2526208A4 (fr) * | 2010-01-21 | 2014-01-15 | Sequella Inc | Méthodes et compositions améliorées pour la détermination du statut pathogène d'agents infectieux |
RU2715591C1 (ru) * | 2016-08-04 | 2020-03-02 | Оптифарм.Ко., Лтд | Диагностический способ и набор для одновременного обнаружения и идентификации туберкулезной микобактерии и нетуберкулезных микобактерий и определения рифампициновой устойчивости туберкулезной микобактерии на основе аналитической платформы quantamatrix |
CN112933952A (zh) * | 2021-02-02 | 2021-06-11 | 东莞市科伟环保电力有限公司 | 一种基于大数据的pncr脱硝优化系统 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101155973B1 (ko) * | 2009-07-07 | 2012-06-18 | 엠앤디 (주) | 결핵균 약제 내성 진단용 프로브 및 그 키트 |
EP2816123B1 (fr) | 2010-02-24 | 2018-09-12 | The Broad Institute, Inc. | Méthodes de diagnostic des agents pathogènes de maladies infectieuses et leur sensibilité aux médicaments |
KR101492561B1 (ko) | 2012-05-25 | 2015-02-11 | 경상대학교산학협력단 | 항생제 내성균 검출용 마이크로어레이 및 이를 이용한 항생제 내성균 분석 방법 |
CN109797193A (zh) * | 2019-02-15 | 2019-05-24 | 安徽理工大学 | 一种结核分枝杆菌耐药性检测方法 |
KR102247643B1 (ko) * | 2019-11-01 | 2021-05-03 | 바이오파크진단 주식회사 | 결핵균 및 비결핵항산균을 검출하기 위한 2단계 진단방법 및 키트 |
KR102524159B1 (ko) * | 2020-10-26 | 2023-04-24 | 한양대학교 에리카산학협력단 | 결핵, 비결핵 항산균 감염질환 및 잠복결핵 진단용 바이오마커 및 이의 용도 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029212A1 (fr) * | 1996-02-08 | 1997-08-14 | Affymetrix, Inc. | Speciation de micro-organismes a partir de microplaquettes et caracterisation des phenotypes de ceux-ci |
EP1076099A2 (fr) * | 1999-08-03 | 2001-02-14 | Nisshinbo Industries, Inc. | Trousse pour la diagnose des bacilles de tubercule |
KR20030008620A (ko) * | 2001-07-19 | 2003-01-29 | 주식회사 제니스라이프사이언스 | 마이코박테리아의 동정 및 rpoB 유전자의 돌연변이에의해 얻어지는 항 결핵제 내성의 동시 검출방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69323872T3 (de) * | 1992-04-30 | 2010-06-02 | Assistance Publique, Hopitaux De Paris | Schnellnachweis der antibiotikaresistenz in mycobacterium tuberculosis |
US5643723A (en) * | 1994-05-26 | 1997-07-01 | Roche Molecular Systems, Inc. | Detection of a genetic locus encoding resistance to rifampin in mycobacterial cultures and in clinical specimens |
PT771360E (pt) * | 1994-06-09 | 2004-07-30 | Innogenetics Nv | Metodo para a deteccao do espectro de resistencia a antibioticos de especies mycobacterium |
KR100285254B1 (ko) * | 1998-05-28 | 2001-04-02 | 국윤호 | 결핵균 및 비결핵균 항산성균의 탐지용 진단시약 |
KR100433260B1 (ko) * | 2000-09-15 | 2004-05-24 | 주식회사 에스제이하이테크 | 멀티플렉스 pcr 방법 및 이를 이용한 마이코박테리아동정용 키트 및 올리고 뉴클레오티드 |
-
2001
- 2001-10-09 KR KR10-2001-0062125A patent/KR100454585B1/ko not_active Expired - Fee Related
-
2002
- 2002-10-09 WO PCT/KR2002/001885 patent/WO2003031654A1/fr not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029212A1 (fr) * | 1996-02-08 | 1997-08-14 | Affymetrix, Inc. | Speciation de micro-organismes a partir de microplaquettes et caracterisation des phenotypes de ceux-ci |
EP1076099A2 (fr) * | 1999-08-03 | 2001-02-14 | Nisshinbo Industries, Inc. | Trousse pour la diagnose des bacilles de tubercule |
KR20030008620A (ko) * | 2001-07-19 | 2003-01-29 | 주식회사 제니스라이프사이언스 | 마이코박테리아의 동정 및 rpoB 유전자의 돌연변이에의해 얻어지는 항 결핵제 내성의 동시 검출방법 |
Non-Patent Citations (3)
Title |
---|
GINGERAS ET AL.: "Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic mycobacterium DNA arrays", GENOME RESEARCH, vol. 8, 1998, pages 435 - 448, XP002156298 * |
ROSSAU ET AL.: "Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of mycobacterium tuberculosis complex and its resistance to rifampin", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 41, no. 10, 1997, pages 2093 - 2098, XP002960364 * |
TROESCH ET AL.: "Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 37, no. 1, 1999, pages 49 - 55 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1580281A3 (fr) * | 2003-09-29 | 2006-09-13 | Eppendorf Ag | Procédé pour determiner la résistance microbienne aux antibiotiques |
WO2005035785A3 (fr) * | 2003-10-10 | 2006-04-20 | Bertin Technologies Sa | Methode de detection rapide de micro-organismes sur puces a adn |
FR2860801A1 (fr) * | 2003-10-10 | 2005-04-15 | Bertin Technologies Sa | Methode de detection rapide de micro-organismes sur puces a adn |
JP2007521829A (ja) * | 2004-02-11 | 2007-08-09 | ヘルス プロテクション エージェンシー | Tb耐性アッセイ |
WO2005078131A1 (fr) * | 2004-02-11 | 2005-08-25 | Health Protection Agency | Dosage de resistance a tb |
AU2005213527B2 (en) * | 2004-02-11 | 2010-05-20 | The Secretary Of State For Health | TB resistance assay |
US7332597B2 (en) | 2004-06-28 | 2008-02-19 | University Of Kentucky Research Foundation | Primers and probe to identify mycobacterium tuberculosis complex |
US7657381B2 (en) | 2004-09-14 | 2010-02-02 | Samsung Electronics Co., Ltd. | Method of designing probe set, microarray having substrate on which probe designed by the method is immobilized, and computer readable medium on which program for executing the method is recorded |
EP1634959A3 (fr) * | 2004-09-14 | 2006-03-22 | Samsung Electronics Co.,Ltd. | Procédé de conception d'un jeu de sondes, micro-réseau l'utilisant, support lisible par ordinateur muni d'un programme pour exécuter ladite méthode |
WO2007018563A3 (fr) * | 2004-10-05 | 2007-06-21 | Wyeth Corp | Ensembles de sondes de detection de multiples souches de differentes especes |
WO2006097232A3 (fr) * | 2005-03-18 | 2007-02-01 | Eppendorf Ag | Detection d'une sensibilite aux antibiotiques et de facteurs de virulence chez pseudomonas aeruginosa |
CN1995380B (zh) * | 2006-01-05 | 2010-05-12 | 中国人民解放军总医院第二附属医院 | 一种检测和鉴定分枝杆菌菌种的方法及其专用试剂盒 |
EP2179041A4 (fr) * | 2007-06-22 | 2010-12-22 | Ibis Biosciences Inc | Compositions et procédés permettant d'identifier des caractéristiques de sous-espèces de mycobacterium tuberculosis |
JP2013502922A (ja) * | 2009-08-26 | 2013-01-31 | エルジー ライフ サイエンス リミテッド | M.ツベルクローシス(m.tuberculosis)群、およびマイコバクテリア(mycobacteria)属を検出するための組成物と、同組成物を用いたマルチプレックスリアルタイムpcrによりm.ツベルクローシス(m.tuberculosis)群、およびマイコバクテリア(mycobacteria)属を同時に検出する方法 |
EP2526208A4 (fr) * | 2010-01-21 | 2014-01-15 | Sequella Inc | Méthodes et compositions améliorées pour la détermination du statut pathogène d'agents infectieux |
RU2715591C1 (ru) * | 2016-08-04 | 2020-03-02 | Оптифарм.Ко., Лтд | Диагностический способ и набор для одновременного обнаружения и идентификации туберкулезной микобактерии и нетуберкулезных микобактерий и определения рифампициновой устойчивости туберкулезной микобактерии на основе аналитической платформы quantamatrix |
CN112933952A (zh) * | 2021-02-02 | 2021-06-11 | 东莞市科伟环保电力有限公司 | 一种基于大数据的pncr脱硝优化系统 |
Also Published As
Publication number | Publication date |
---|---|
KR20030030266A (ko) | 2003-04-18 |
KR100454585B1 (ko) | 2004-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hermans et al. | Insertion element IS986 from Mycobacterium tuberculosis: a useful tool for diagnosis and epidemiology of tuberculosis | |
KR100454585B1 (ko) | 마이코박테리아의 균주 감별, 결핵균의 스트레인 감별과항생제 내성을 검출하기 위한 프로브를 포함하는마이크로어레이와 이를 이용한 검출 방법 및 진단 키트 | |
Guo et al. | Rapid, accurate determination of multidrug resistance in M. tuberculosis isolates and sputum using a biochip system | |
Ross et al. | Identification of a genetically distinct subspecies of Mycobacterium kansasii | |
EP1746156B1 (fr) | Sonde et amorce pour la detection du bacille tuberculeux et procede de detection du bacille tuberculeux humain avec celles-ci | |
Antonova et al. | Detection of mutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological microchips | |
Mijs et al. | Evaluation of a commercial line probe assay for identification of Mycobacterium species from liquid and solid culture | |
Isola et al. | A Pyrosequencing assay for rapid recognition of SNPs in Mycobacterium tuberculosis embB306 region | |
Yue et al. | Detection of rifampin-resistant Mycobacterium tuberculosis strains by using a specialized oligonucleotide microarray | |
KR100433260B1 (ko) | 멀티플렉스 pcr 방법 및 이를 이용한 마이코박테리아동정용 키트 및 올리고 뉴클레오티드 | |
US7271781B2 (en) | Multiplex hybridization system for identification of pathogenic mycobacterium and method of use | |
WO2003008645A1 (fr) | Procede permettant d'identifier mycobacterium tuberculosis et une mycobacterie autre que tuberculeuse, ainsi que de detecter la resistance a un medicament antituberculeux de mycobacterium, obtenue par mutation du gene rpob | |
EP2677040A1 (fr) | Sonde, puce, kit et procédé pour la détection de Mycobacterium tuberculosis, Mycobacteria non-tuberculeuses et Mycobacterium tuberculosis résistante aux médicaments | |
KR100673090B1 (ko) | 결핵균의 항생제 내성을 검출하기 위한 프로브를 포함하는마이크로어레이와 이를 이용한 검출 방법 및 진단 키트 | |
JP3631252B2 (ja) | 直列変異反復配列オリゴタイピングによる結核菌群細菌の検出および鑑別 | |
Glennon et al. | Detection and diagnosis of mycobacterial pathogens using PCR | |
EP1248854B1 (fr) | FRAGMENTS DE GENE rpoB ET PROCEDE DE DIAGNOSTIC ET D'IDENTIFICATION DE SOUCHES MYCOBACTERIENNES DE MYCOBACTERIUM TUBERCULOSIS ET NON-TUBERCULOSIS | |
JP3360736B2 (ja) | ミコバクテリア属微生物を特異的に認識するプローブ及びミコバクテリア属微生物の検出方法 | |
Koivula et al. | Genetic diversity in clinical isolates of Mycobacterium avium complex from Guinea-Bissau, West Africa | |
Forbes et al. | Molecular diagnosis of mycobacterial infections | |
Therese et al. | Molecular biological techniques for detection of multidrug resistant tuberculosis (MDR) and extremely drug resistant tuberculosis (XDR) in clinical isolates of Mycobacterium tuberculosis | |
Bai et al. | PCR-linked reverse DNA hybridization using oligonucleotide-specific probes of rpoB for identification of Mycobacterium avium and Mycobacterium intracellulare | |
Sritharan et al. | Polymerase chain reaction in the diagnosis of tuberculosis | |
Martín et al. | New methods for diagnosis and epidemiological studies of tuberculosis based on PCR and RFLP | |
Williams | PCR and Diagnosis of Tuberculosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |